Source comparison
MOTS-c Dosage Aging Metabolism 2026: Comparison
Standard Longevity 5mg subcutaneous 2x weekly (72-96hr apart) 10mg/week Metabolic preservation in healthy adults 40+ Maintains insulin sensitivity comparable to younger baseline; prevents age-related mitochondrial decline Gold standard for preventive metabolic
This comparison does not assign a generated winner or score.
- Standard Longevity
- 5mg subcutaneous
- 2x weekly (72-96hr apart)
- 10mg/week
- Metabolic preservation in healthy adults 40+
- Maintains insulin sensitivity comparable to younger baseline; prevents age-related mitochondrial decline
- Gold standard for preventive metabolic aging intervention. Backed by longest safety data
- Metabolic Intervention
- 10mg subcutaneous
- 3x weekly (48-72hr apart)
- 30mg/week
- Insulin resistance, metabolic syndrome, HbA1c >5.7%
- HbA1c reduction 0.4-0.6%, fasting glucose reduction 8-12 mg/dL, improved glucose disposal rate 18-25%
- Appropriate for clinical metabolic dysfunction. Requires transition to maintenance dose after 8-12 weeks
- Microdosing (not recommended)
- 2mg subcutaneous
- Daily
- 14mg/week
- Theoretical 'steady-state' approach
- Minimal clinical data; no published trials show superiority over twice-weekly protocols
- Lacks evidence base. Daily injections increase injection site reactions without improving metabolic markers
- High-Dose (not recommended)
- 15mg+ subcutaneous
- 2-3x weekly
- 30-45mg/week
- None validated
- No additional metabolic benefit vs 10mg dose; increased adverse event rate
- Exceeds therapeutic ceiling. Wasteful and increases risk profile unnecessarily